February 2012 Vol 5, No 1, Special Issue - Leukemia
Neil Canavan
Medical Writer
Neil Canavan
Medical Writer

Preliminary data from the phase 2 PACE (Ponatinib Ph+ALL and CML Evaluation) trial show that ponatinib (Ariad Pharmaceuticals) can overcome the difficult-to-treat T315I mutation in patients with chronic myeloid leukemia (CML). Currently, patients with this genetic mutation have no effective treatment options.

In PACE, the tyrosine kinase inhibitor (TKI) ponatinib achieved a 47% major cytogenetic response (MCyR). For patients with the T315I mutation, ponatinib induced a 65% MCyR. This drug was specifically designed to overcome the T315I mutation.

“Ponatinib has the potential to become a promising new treatment option for patients with multi-refractory/relapsed CML,” said PACE lead investigator Jorge E. Cortes, MD, of the University of Texas M.D. Anderson Cancer Center, Houston.

This open-label study enrolled 499 patients with CML or with Philadel­phia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) who had previously been treated with nilotinib or dasatinib, but their disease was resistant or intolerant to those drugs, or they had the T315I mutation.

Patients were stratified into 1 of 6 groups, according to disease, disease phase, and mutation status. All patients were treated with the same dose and schedule. The primary end points were MCyR for chronic-phase (CP)-CML, and major histologic re­sponse for accelerated-phase (AP)-CML, blast-phase (BP)-CML, or Ph+ALL.

After a median follow-up of 5 months, Dr Cortes reported high levels of response being observed in all patient types. Patients with AP-CML achieved a major histologic response of 74%, and MCyRs ranging up to 53%. For patients with the most severe prognosis, the BP-CML and Ph+ALL cohorts, both groups achieved a major histologic response of 37%, and MCyRs of 34% and 37%, respectively.

A major molecular response rate of 33% was reported in patients with the T315I mutation and those with CP-CML/T315I.

Treatment-related adverse events were generally mild; the most common serious events were thrombocytopenia and neutropenia.

“Extremely exciting,” said Tim Brümmendorf, MD, of the University Hospital, Aachen, Germany, in re­sponse to the ponatinib data. “It is the most promising approach to target the most problematic mutation that we currently see—the T315I mutation. This mutation confers absolute resis­tance to all TKIs that we currently have approved in clinical use. So, from what I have seen, it [ponatinib] looks extremely promising.”

Related Items
First Cost Analysis of Long-Term Management of CML
Neil Canavan, Neil Canavan
February 2012 Vol 5, No 1, Special Issue published on February 24, 2012 in Health Economics, Health Economics
Hematologists Are Told to Get Ready for ACOs
Neil Canavan, Neil Canavan
February 2012 Vol 5, No 1, Special Issue published on February 23, 2012 in Health Economics, Health Economics
Bosutinib Shows Superior Results in CML
Neil Canavan, Neil Canavan
February 2012 Vol 5, No 1, Special Issue published on February 23, 2012 in Leukemia
Novel Oral B-Cell Receptor Inhibitor Very Effective in Chronic Lymphocytic Leukemia
Caroline Helwick, Caroline Helwick, Caroline Helwick
February 2012 Vol 5, No 1, Special Issue published on February 23, 2012 in Leukemia
Ready-Made Platelets? A Boon for Patients If It Works
Neil Canavan, Neil Canavan
February 2012 Vol 5, No 1, Special Issue published on February 23, 2012 in Conference Highlights ASH
Last modified: March 16, 2012
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME